Notably, the pioneering CANTOS trial has showcased improved outcomes in atherosclerosis patients treated with Canakinumab—a human monoclonal antibody against IL-1β—thereby establishing a tangible proof of concept 33. Here, IL1B is linked to atherosclerosis.